# OnCo record nala (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nala/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nala", "NCT01808573" ;
  schema:name "NALA"@en ;
  schema:description "NALA showed that the irreversible HER2 inhibitor neratinib, given with capecitabine, kept heavily pretreated HER2-positive breast cancer under control for longer than lapatinib and reduced the need for treatment of brain metastases."@en ;
  schema:url <https://onco.cc/trials/nala/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01808573> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/her2-positive-breast-brain-metastases/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:drugs <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/lapatinib/> ;
  onco:companies <https://onco.cc/companies/puma-biotechnology/> ;
  onco:people <https://onco.cc/people/cristina-saura/> .